i
Hepatitis B Surface Antigen Screening Among Pregnant Women and Care of Infants of Hepatitis B Surface Antigen–Positive Mothers — Guam, 2014
-
May 19 2017
Source: MMWR Morb Mortal Wkly Rep. 66(19):506-508. -
Alternative Title:MMWR Morb Mortal Wkly Rep
-
Publisher's site:
-
Personal Author:
-
Corporate Authors:National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.)Division of Sexually Transmitted Diseases Prevention. ; National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.)Division of Viral Hepatitis. ; Centers for Dsease Control and Prevention (U.S.)Epidemic Intelligence Service.
-
Description:Hepatitis B Virus (HBV) infection is endemic among adults in the U.S. territory of Guam (1,2). Perinatal HBV Transmission, which occurs at birth from an infected mother to her newborn infant, is a major mode of HBV Transmission and maintains HBV endemicity (3). Approximately 90% of HBV-infected infants will develop chronic HBV infection, and approximately 25% of those will die prematurely from liver failure or hepatocellular carcinoma (4,5). Since 1988, the Advisory Committee on Immunization Practices has recommended that all pregnant women be screened for hepatitis B surface antigen (HBsAg), an indicator of HBV infection, and that infants of women who screen positive (HBsAg-positive women) receive postexposure prophylaxis (PEP) (hepatitis B vaccine and hepatitis B immunoglobulin [HBIG]). When received within 12 hours of birth, PEP is 85%-95% effective in preventing perinatal HBV Transmission (5,6). Hepatitis B vaccine provides long-term active immunity to HBV infection and HBIG provides short-term passive immunity to HBV infection until the infant responds to the vaccine (5). Hepatitis B vaccine was introduced into the routine universal infant vaccination schedule in Guam in 1988 (1).
-
Subjects:
-
Pubmed ID:28520708
-
Pubmed Central ID:PMC5657642
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: